A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activity
A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activity